Review



ctni primary antibody 1ab stock solution  (HyTest)


Bioz Verified Symbol HyTest is a verified supplier
Bioz Manufacturer Symbol HyTest manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    HyTest ctni primary antibody 1ab stock solution
    Figure 1. Gold secondary antibody was employed for <t>cTnI</t> detection, as shown in the plot: (A) entire spectrum absorption. The linearity for the different concentrations are all close to 0, indicating the wavelength and intensity do not have a linear correlation. While R2 is larger than 0.95, indicating all spectra are good fits in the quadratic curve; (B) absorption following blank-plate background correction, and (C) red shift vs log cTnI concentration. Indicate *c, the error bar decreased as cTnI concentration increased, indicating that studying an antibody’s dilution ratio can enhance resolution.
    Ctni Primary Antibody 1ab Stock Solution, supplied by HyTest, used in various techniques. Bioz Stars score: 96/100, based on 179 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ctni+primary+antibody+1ab+stock+solution/cTnI/pm39144556-43-1-16
    Average 96 stars, based on 179 article reviews
    ctni primary antibody 1ab stock solution - by Bioz Stars, 2026-09
    96/100 stars

    Images

    1) Product Images from "Rapid-Test Kit for Cardiac Troponin I: A Reliable Enzyme-Linked-Immuno-Substrate-Assay-Based Biosensor for Daily-Use Naked-Eye Detection and Pharmacokinetic Studies for Myocardial Infarction in Cardiovascular Disease."

    Article Title: Rapid-Test Kit for Cardiac Troponin I: A Reliable Enzyme-Linked-Immuno-Substrate-Assay-Based Biosensor for Daily-Use Naked-Eye Detection and Pharmacokinetic Studies for Myocardial Infarction in Cardiovascular Disease.

    Journal: ACS pharmacology & translational science

    doi: 10.1021/acsptsci.4c00218

    Figure 1. Gold secondary antibody was employed for cTnI detection, as shown in the plot: (A) entire spectrum absorption. The linearity for the different concentrations are all close to 0, indicating the wavelength and intensity do not have a linear correlation. While R2 is larger than 0.95, indicating all spectra are good fits in the quadratic curve; (B) absorption following blank-plate background correction, and (C) red shift vs log cTnI concentration. Indicate *c, the error bar decreased as cTnI concentration increased, indicating that studying an antibody’s dilution ratio can enhance resolution.
    Figure Legend Snippet: Figure 1. Gold secondary antibody was employed for cTnI detection, as shown in the plot: (A) entire spectrum absorption. The linearity for the different concentrations are all close to 0, indicating the wavelength and intensity do not have a linear correlation. While R2 is larger than 0.95, indicating all spectra are good fits in the quadratic curve; (B) absorption following blank-plate background correction, and (C) red shift vs log cTnI concentration. Indicate *c, the error bar decreased as cTnI concentration increased, indicating that studying an antibody’s dilution ratio can enhance resolution.

    Techniques Used: Concentration Assay

    Figure 4. Secondary antibody dilution ratio with (A) different ratios, (B) 145× dilution, and (C) 1562.5× dilution. * Denotes that the reference wells contained 0 to 8 ng/mL standard cTnI protein; ** denotes that the sample contained human serum spiked with standard cTnI protein at three concentrations.
    Figure Legend Snippet: Figure 4. Secondary antibody dilution ratio with (A) different ratios, (B) 145× dilution, and (C) 1562.5× dilution. * Denotes that the reference wells contained 0 to 8 ng/mL standard cTnI protein; ** denotes that the sample contained human serum spiked with standard cTnI protein at three concentrations.

    Techniques Used:

    Figure 3. cTnI detection model. (A) Standard curve calibrated at 450 nm absorbance. The arrow indicates the area used to increase resolution and also indicates the area of human cTnI with MI, which can vary and is highly dependent on the individual; (B) color change can be seen by the naked eye; color gradually changes in response to the cTnI concentration increased from 0.064 to 8.00 ng/mL.
    Figure Legend Snippet: Figure 3. cTnI detection model. (A) Standard curve calibrated at 450 nm absorbance. The arrow indicates the area used to increase resolution and also indicates the area of human cTnI with MI, which can vary and is highly dependent on the individual; (B) color change can be seen by the naked eye; color gradually changes in response to the cTnI concentration increased from 0.064 to 8.00 ng/mL.

    Techniques Used: Concentration Assay

    Figure 6. Schematic illustrating the pricking of blood at the clinic or home for MI self-diagnosis. (A) Pricking a finger and adding one drop of blood into one sample well every 30 min; * indicates the reference wells. (B) Adding the reagents. (C) Self-diagnosing MI based on the yellow pattern, where the yellow color denotes a positive diagnosis. After comparing samples to the reference well and multiplying the converting factor, the doctor or patient can determine the cTnI protein concentration at each time point. Conversion factor 15 ± 7.14 for human serum and 1.84 ± 0.76 for 10× dilute human serum. For pricking point-of-care, 1.84 ± 0.76 can be an approximate conversion factor.
    Figure Legend Snippet: Figure 6. Schematic illustrating the pricking of blood at the clinic or home for MI self-diagnosis. (A) Pricking a finger and adding one drop of blood into one sample well every 30 min; * indicates the reference wells. (B) Adding the reagents. (C) Self-diagnosing MI based on the yellow pattern, where the yellow color denotes a positive diagnosis. After comparing samples to the reference well and multiplying the converting factor, the doctor or patient can determine the cTnI protein concentration at each time point. Conversion factor 15 ± 7.14 for human serum and 1.84 ± 0.76 for 10× dilute human serum. For pricking point-of-care, 1.84 ± 0.76 can be an approximate conversion factor.

    Techniques Used: Biomarker Discovery, Protein Concentration

    Figure 5. Schematic illustrating the naked-eye cTnI detection device in (A) sample wells; (B) reference wells; (C) blood loading on the sample well, with the red arrow representing blood flow; (D) PBS loading on the reference well, with the black arrow denoting PBS flow; (E,F) secondary antibody loading and chromophore acting. Different items indicate antibody (red Y-shape), BSA (blue ball), cTnI protein (gray), HRP (blue pistachio), and TMB chromophore (black ball). (A,C,E) represent sample wells, while (B,D,F) represent reference wells. The difference between sample and reference wells is that reference wells in the first step were already coated with standard cTnI protein, serving as calibration wells.
    Figure Legend Snippet: Figure 5. Schematic illustrating the naked-eye cTnI detection device in (A) sample wells; (B) reference wells; (C) blood loading on the sample well, with the red arrow representing blood flow; (D) PBS loading on the reference well, with the black arrow denoting PBS flow; (E,F) secondary antibody loading and chromophore acting. Different items indicate antibody (red Y-shape), BSA (blue ball), cTnI protein (gray), HRP (blue pistachio), and TMB chromophore (black ball). (A,C,E) represent sample wells, while (B,D,F) represent reference wells. The difference between sample and reference wells is that reference wells in the first step were already coated with standard cTnI protein, serving as calibration wells.

    Techniques Used:

    Figure 8. Naked-eye cTnI detection device under a human serum matrix effect (A) spiked or (B) nonspiked with cTnI protein. The 10× diluted human serum (C) spiked or (D) nonspiked with cTnI protein. A spiked sample represents a patient sample (black arrow), while a nonspiked sample denotes a healthy sample. Black arrows represent 0, 0.5, and 1 h time points (from right to left) after the patient’s first blood- pricking. Each time point blood-prick once. * indicates 0, 0.064, 0.32, 1.60, and 8.00 ng/mL of cTnI protein as the reference wells from right to left and are the same in these four well strips. This device can distinguish between an MI and a healthy patient.
    Figure Legend Snippet: Figure 8. Naked-eye cTnI detection device under a human serum matrix effect (A) spiked or (B) nonspiked with cTnI protein. The 10× diluted human serum (C) spiked or (D) nonspiked with cTnI protein. A spiked sample represents a patient sample (black arrow), while a nonspiked sample denotes a healthy sample. Black arrows represent 0, 0.5, and 1 h time points (from right to left) after the patient’s first blood- pricking. Each time point blood-prick once. * indicates 0, 0.064, 0.32, 1.60, and 8.00 ng/mL of cTnI protein as the reference wells from right to left and are the same in these four well strips. This device can distinguish between an MI and a healthy patient.

    Techniques Used:

    Figure 7. Naked-eye cTnI detection device was tested and passed 7 months of life-shelf absorbance detectable data with (A) standard and (B) sample at day 1 and 7 months later. In addition, (C) device comprises three rows in a portable, disposable bag and can be assembled onto a 96-well frame. (D) Strips are sealed in an airtight package and stored at 4 °C after the fabrication. 7-month data shows color decreasing both at the sample and standard, but with the standard curve fitting, showing that the result is repetitive and readable.
    Figure Legend Snippet: Figure 7. Naked-eye cTnI detection device was tested and passed 7 months of life-shelf absorbance detectable data with (A) standard and (B) sample at day 1 and 7 months later. In addition, (C) device comprises three rows in a portable, disposable bag and can be assembled onto a 96-well frame. (D) Strips are sealed in an airtight package and stored at 4 °C after the fabrication. 7-month data shows color decreasing both at the sample and standard, but with the standard curve fitting, showing that the result is repetitive and readable.

    Techniques Used:

    Figure 9. Standard curve of cTnI protein between the proposed test strip and a commercial ELISA plate. The R2 of the proposed test strip is 0.9645. The linearity is (R2)1/2 = 0.9821.
    Figure Legend Snippet: Figure 9. Standard curve of cTnI protein between the proposed test strip and a commercial ELISA plate. The R2 of the proposed test strip is 0.9645. The linearity is (R2)1/2 = 0.9821.

    Techniques Used: Stripping Membranes, Enzyme-linked Immunosorbent Assay

    Related Articles

    Saline:

    Article Title: Rapid-Test Kit for Cardiac Troponin I: A Reliable Enzyme-Linked-Immuno-Substrate-Assay-Based Biosensor for Daily-Use Naked-Eye Detection and Pharmacokinetic Studies for Myocardial Infarction in Cardiovascular Disease.
    Article Snippet: The 96-well plate (SIWARDLSPR02 or Corning 3596 clear bottom high-bind 96- well plate) is assembled. .. The cTnI primary antibody (1Ab) stock solution is prepared as follows: 2 μg/mL monoclonal mouse anti-cTnI (HyTest 4T21 cm3, 25 kDa) is dissolved in phosphate-buffered saline (PBS), and a multichannel pipet was used to add 100 μL/well. ..

    Article Title: Rapid-Test Kit Creation of Cardiac Troponin I, A Reliable Biosensor for Naked-Eye Detection Method in Daily Usage and Pharmacokinetic Studies for myocardial Infarction, Systemic Amyloidosis, and Cardiovascular Disease
    Article Snippet: .. Prepare 78 the cTnI primary antibody (1Ab) stock solution as follows: dissolve monoclonal mouse 79 anti-cTnI (HyTest 4T21cc, 25 kDa) 2 g/mL in phosphate buffered saline (PBS). ..



    Similar Products

    96
    HyTest ctni primary antibody 1ab stock solution
    Figure 1. Gold secondary antibody was employed for <t>cTnI</t> detection, as shown in the plot: (A) entire spectrum absorption. The linearity for the different concentrations are all close to 0, indicating the wavelength and intensity do not have a linear correlation. While R2 is larger than 0.95, indicating all spectra are good fits in the quadratic curve; (B) absorption following blank-plate background correction, and (C) red shift vs log cTnI concentration. Indicate *c, the error bar decreased as cTnI concentration increased, indicating that studying an antibody’s dilution ratio can enhance resolution.
    Ctni Primary Antibody 1ab Stock Solution, supplied by HyTest, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ctni+primary+antibody+1ab+stock+solution/cTnI/pm39144556-43-1-16
    Average 96 stars, based on 1 article reviews
    ctni primary antibody 1ab stock solution - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    Image Search Results


    Figure 1. Gold secondary antibody was employed for cTnI detection, as shown in the plot: (A) entire spectrum absorption. The linearity for the different concentrations are all close to 0, indicating the wavelength and intensity do not have a linear correlation. While R2 is larger than 0.95, indicating all spectra are good fits in the quadratic curve; (B) absorption following blank-plate background correction, and (C) red shift vs log cTnI concentration. Indicate *c, the error bar decreased as cTnI concentration increased, indicating that studying an antibody’s dilution ratio can enhance resolution.

    Journal: ACS pharmacology & translational science

    Article Title: Rapid-Test Kit for Cardiac Troponin I: A Reliable Enzyme-Linked-Immuno-Substrate-Assay-Based Biosensor for Daily-Use Naked-Eye Detection and Pharmacokinetic Studies for Myocardial Infarction in Cardiovascular Disease.

    doi: 10.1021/acsptsci.4c00218

    Figure Lengend Snippet: Figure 1. Gold secondary antibody was employed for cTnI detection, as shown in the plot: (A) entire spectrum absorption. The linearity for the different concentrations are all close to 0, indicating the wavelength and intensity do not have a linear correlation. While R2 is larger than 0.95, indicating all spectra are good fits in the quadratic curve; (B) absorption following blank-plate background correction, and (C) red shift vs log cTnI concentration. Indicate *c, the error bar decreased as cTnI concentration increased, indicating that studying an antibody’s dilution ratio can enhance resolution.

    Article Snippet: The cTnI primary antibody (1Ab) stock solution is prepared as follows: 2 μg/mL monoclonal mouse anti-cTnI (HyTest 4T21 cm3, 25 kDa) is dissolved in phosphate-buffered saline (PBS), and a multichannel pipet was used to add 100 μL/well.

    Techniques: Concentration Assay

    Figure 4. Secondary antibody dilution ratio with (A) different ratios, (B) 145× dilution, and (C) 1562.5× dilution. * Denotes that the reference wells contained 0 to 8 ng/mL standard cTnI protein; ** denotes that the sample contained human serum spiked with standard cTnI protein at three concentrations.

    Journal: ACS pharmacology & translational science

    Article Title: Rapid-Test Kit for Cardiac Troponin I: A Reliable Enzyme-Linked-Immuno-Substrate-Assay-Based Biosensor for Daily-Use Naked-Eye Detection and Pharmacokinetic Studies for Myocardial Infarction in Cardiovascular Disease.

    doi: 10.1021/acsptsci.4c00218

    Figure Lengend Snippet: Figure 4. Secondary antibody dilution ratio with (A) different ratios, (B) 145× dilution, and (C) 1562.5× dilution. * Denotes that the reference wells contained 0 to 8 ng/mL standard cTnI protein; ** denotes that the sample contained human serum spiked with standard cTnI protein at three concentrations.

    Article Snippet: The cTnI primary antibody (1Ab) stock solution is prepared as follows: 2 μg/mL monoclonal mouse anti-cTnI (HyTest 4T21 cm3, 25 kDa) is dissolved in phosphate-buffered saline (PBS), and a multichannel pipet was used to add 100 μL/well.

    Techniques:

    Figure 3. cTnI detection model. (A) Standard curve calibrated at 450 nm absorbance. The arrow indicates the area used to increase resolution and also indicates the area of human cTnI with MI, which can vary and is highly dependent on the individual; (B) color change can be seen by the naked eye; color gradually changes in response to the cTnI concentration increased from 0.064 to 8.00 ng/mL.

    Journal: ACS pharmacology & translational science

    Article Title: Rapid-Test Kit for Cardiac Troponin I: A Reliable Enzyme-Linked-Immuno-Substrate-Assay-Based Biosensor for Daily-Use Naked-Eye Detection and Pharmacokinetic Studies for Myocardial Infarction in Cardiovascular Disease.

    doi: 10.1021/acsptsci.4c00218

    Figure Lengend Snippet: Figure 3. cTnI detection model. (A) Standard curve calibrated at 450 nm absorbance. The arrow indicates the area used to increase resolution and also indicates the area of human cTnI with MI, which can vary and is highly dependent on the individual; (B) color change can be seen by the naked eye; color gradually changes in response to the cTnI concentration increased from 0.064 to 8.00 ng/mL.

    Article Snippet: The cTnI primary antibody (1Ab) stock solution is prepared as follows: 2 μg/mL monoclonal mouse anti-cTnI (HyTest 4T21 cm3, 25 kDa) is dissolved in phosphate-buffered saline (PBS), and a multichannel pipet was used to add 100 μL/well.

    Techniques: Concentration Assay

    Figure 6. Schematic illustrating the pricking of blood at the clinic or home for MI self-diagnosis. (A) Pricking a finger and adding one drop of blood into one sample well every 30 min; * indicates the reference wells. (B) Adding the reagents. (C) Self-diagnosing MI based on the yellow pattern, where the yellow color denotes a positive diagnosis. After comparing samples to the reference well and multiplying the converting factor, the doctor or patient can determine the cTnI protein concentration at each time point. Conversion factor 15 ± 7.14 for human serum and 1.84 ± 0.76 for 10× dilute human serum. For pricking point-of-care, 1.84 ± 0.76 can be an approximate conversion factor.

    Journal: ACS pharmacology & translational science

    Article Title: Rapid-Test Kit for Cardiac Troponin I: A Reliable Enzyme-Linked-Immuno-Substrate-Assay-Based Biosensor for Daily-Use Naked-Eye Detection and Pharmacokinetic Studies for Myocardial Infarction in Cardiovascular Disease.

    doi: 10.1021/acsptsci.4c00218

    Figure Lengend Snippet: Figure 6. Schematic illustrating the pricking of blood at the clinic or home for MI self-diagnosis. (A) Pricking a finger and adding one drop of blood into one sample well every 30 min; * indicates the reference wells. (B) Adding the reagents. (C) Self-diagnosing MI based on the yellow pattern, where the yellow color denotes a positive diagnosis. After comparing samples to the reference well and multiplying the converting factor, the doctor or patient can determine the cTnI protein concentration at each time point. Conversion factor 15 ± 7.14 for human serum and 1.84 ± 0.76 for 10× dilute human serum. For pricking point-of-care, 1.84 ± 0.76 can be an approximate conversion factor.

    Article Snippet: The cTnI primary antibody (1Ab) stock solution is prepared as follows: 2 μg/mL monoclonal mouse anti-cTnI (HyTest 4T21 cm3, 25 kDa) is dissolved in phosphate-buffered saline (PBS), and a multichannel pipet was used to add 100 μL/well.

    Techniques: Biomarker Discovery, Protein Concentration

    Figure 5. Schematic illustrating the naked-eye cTnI detection device in (A) sample wells; (B) reference wells; (C) blood loading on the sample well, with the red arrow representing blood flow; (D) PBS loading on the reference well, with the black arrow denoting PBS flow; (E,F) secondary antibody loading and chromophore acting. Different items indicate antibody (red Y-shape), BSA (blue ball), cTnI protein (gray), HRP (blue pistachio), and TMB chromophore (black ball). (A,C,E) represent sample wells, while (B,D,F) represent reference wells. The difference between sample and reference wells is that reference wells in the first step were already coated with standard cTnI protein, serving as calibration wells.

    Journal: ACS pharmacology & translational science

    Article Title: Rapid-Test Kit for Cardiac Troponin I: A Reliable Enzyme-Linked-Immuno-Substrate-Assay-Based Biosensor for Daily-Use Naked-Eye Detection and Pharmacokinetic Studies for Myocardial Infarction in Cardiovascular Disease.

    doi: 10.1021/acsptsci.4c00218

    Figure Lengend Snippet: Figure 5. Schematic illustrating the naked-eye cTnI detection device in (A) sample wells; (B) reference wells; (C) blood loading on the sample well, with the red arrow representing blood flow; (D) PBS loading on the reference well, with the black arrow denoting PBS flow; (E,F) secondary antibody loading and chromophore acting. Different items indicate antibody (red Y-shape), BSA (blue ball), cTnI protein (gray), HRP (blue pistachio), and TMB chromophore (black ball). (A,C,E) represent sample wells, while (B,D,F) represent reference wells. The difference between sample and reference wells is that reference wells in the first step were already coated with standard cTnI protein, serving as calibration wells.

    Article Snippet: The cTnI primary antibody (1Ab) stock solution is prepared as follows: 2 μg/mL monoclonal mouse anti-cTnI (HyTest 4T21 cm3, 25 kDa) is dissolved in phosphate-buffered saline (PBS), and a multichannel pipet was used to add 100 μL/well.

    Techniques:

    Figure 8. Naked-eye cTnI detection device under a human serum matrix effect (A) spiked or (B) nonspiked with cTnI protein. The 10× diluted human serum (C) spiked or (D) nonspiked with cTnI protein. A spiked sample represents a patient sample (black arrow), while a nonspiked sample denotes a healthy sample. Black arrows represent 0, 0.5, and 1 h time points (from right to left) after the patient’s first blood- pricking. Each time point blood-prick once. * indicates 0, 0.064, 0.32, 1.60, and 8.00 ng/mL of cTnI protein as the reference wells from right to left and are the same in these four well strips. This device can distinguish between an MI and a healthy patient.

    Journal: ACS pharmacology & translational science

    Article Title: Rapid-Test Kit for Cardiac Troponin I: A Reliable Enzyme-Linked-Immuno-Substrate-Assay-Based Biosensor for Daily-Use Naked-Eye Detection and Pharmacokinetic Studies for Myocardial Infarction in Cardiovascular Disease.

    doi: 10.1021/acsptsci.4c00218

    Figure Lengend Snippet: Figure 8. Naked-eye cTnI detection device under a human serum matrix effect (A) spiked or (B) nonspiked with cTnI protein. The 10× diluted human serum (C) spiked or (D) nonspiked with cTnI protein. A spiked sample represents a patient sample (black arrow), while a nonspiked sample denotes a healthy sample. Black arrows represent 0, 0.5, and 1 h time points (from right to left) after the patient’s first blood- pricking. Each time point blood-prick once. * indicates 0, 0.064, 0.32, 1.60, and 8.00 ng/mL of cTnI protein as the reference wells from right to left and are the same in these four well strips. This device can distinguish between an MI and a healthy patient.

    Article Snippet: The cTnI primary antibody (1Ab) stock solution is prepared as follows: 2 μg/mL monoclonal mouse anti-cTnI (HyTest 4T21 cm3, 25 kDa) is dissolved in phosphate-buffered saline (PBS), and a multichannel pipet was used to add 100 μL/well.

    Techniques:

    Figure 7. Naked-eye cTnI detection device was tested and passed 7 months of life-shelf absorbance detectable data with (A) standard and (B) sample at day 1 and 7 months later. In addition, (C) device comprises three rows in a portable, disposable bag and can be assembled onto a 96-well frame. (D) Strips are sealed in an airtight package and stored at 4 °C after the fabrication. 7-month data shows color decreasing both at the sample and standard, but with the standard curve fitting, showing that the result is repetitive and readable.

    Journal: ACS pharmacology & translational science

    Article Title: Rapid-Test Kit for Cardiac Troponin I: A Reliable Enzyme-Linked-Immuno-Substrate-Assay-Based Biosensor for Daily-Use Naked-Eye Detection and Pharmacokinetic Studies for Myocardial Infarction in Cardiovascular Disease.

    doi: 10.1021/acsptsci.4c00218

    Figure Lengend Snippet: Figure 7. Naked-eye cTnI detection device was tested and passed 7 months of life-shelf absorbance detectable data with (A) standard and (B) sample at day 1 and 7 months later. In addition, (C) device comprises three rows in a portable, disposable bag and can be assembled onto a 96-well frame. (D) Strips are sealed in an airtight package and stored at 4 °C after the fabrication. 7-month data shows color decreasing both at the sample and standard, but with the standard curve fitting, showing that the result is repetitive and readable.

    Article Snippet: The cTnI primary antibody (1Ab) stock solution is prepared as follows: 2 μg/mL monoclonal mouse anti-cTnI (HyTest 4T21 cm3, 25 kDa) is dissolved in phosphate-buffered saline (PBS), and a multichannel pipet was used to add 100 μL/well.

    Techniques:

    Figure 9. Standard curve of cTnI protein between the proposed test strip and a commercial ELISA plate. The R2 of the proposed test strip is 0.9645. The linearity is (R2)1/2 = 0.9821.

    Journal: ACS pharmacology & translational science

    Article Title: Rapid-Test Kit for Cardiac Troponin I: A Reliable Enzyme-Linked-Immuno-Substrate-Assay-Based Biosensor for Daily-Use Naked-Eye Detection and Pharmacokinetic Studies for Myocardial Infarction in Cardiovascular Disease.

    doi: 10.1021/acsptsci.4c00218

    Figure Lengend Snippet: Figure 9. Standard curve of cTnI protein between the proposed test strip and a commercial ELISA plate. The R2 of the proposed test strip is 0.9645. The linearity is (R2)1/2 = 0.9821.

    Article Snippet: The cTnI primary antibody (1Ab) stock solution is prepared as follows: 2 μg/mL monoclonal mouse anti-cTnI (HyTest 4T21 cm3, 25 kDa) is dissolved in phosphate-buffered saline (PBS), and a multichannel pipet was used to add 100 μL/well.

    Techniques: Stripping Membranes, Enzyme-linked Immunosorbent Assay